Home › Research › Topics › randomized
randomized
804 studies tagged randomized, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
804 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488.
-
This study shows significant therapeutic effects of trazodone 50 mg in community-dwelling AD patients with SD.
-
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology.
-
36/100
The prevalence of Alzheimer's disease is increasing rapidly in the absence of truly effective therapies.
-
Among patients with mild to moderate AD, 2000 IU/d of alpha tocopherol compared with placebo resulted in slower functional decline.
-
Patient treatment with sertraline was not associated with significantly greater reductions in caregiver distress than placebo treatment.
-
We conducted a randomized, cross-over trial to investigate the feasibility, safety, and motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technique in patients with Alzheimer's disease (AD).
-
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers.
-
36/100
Amyloid-β (Aβ) peptides accumulate in the brain and initiate a cascade of pathologic events in Alzheimer's disease.
-
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect.
-
Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD.
-
Huperzine A is a Chinese herb extract used for Alzheimer's disease.
-
Synaptic loss in the brain correlates well with disease severity in Alzheimer disease (AD).
-
In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease.
-
As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.
-
Present results suggest that repeated cycles of CT in patients with AD treated with ChEIs are associated with benefits in several areas of cognitive function.
-
Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)?
-
73/100
An intensive and long-term exercise program had beneficial effects on the physical functioning of patients with AD without increasing the total costs of health and social services or causing any significant adverse effects.
-
Feasibility was demonstrated with regard to recruitment, attrition, and treatment characteristics.
-
The results indicate that short term use of this piperine-enhanced curcuminoid preparation is unlikely to result in a clinically significant interaction involving CYP3A, CYP2C9 or the paracetamol conjugation enzymes.
-
The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
-
The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
-
The specific CB2 cannabinoid receptor agonist JWH-133 induced cognitive improvement in double AβPP/PS1 transgenic mice, a genetic model of Alzheimer's disease.
-
A 2-hour infusion of 0.1 to 10 mg/kg ponezumab was well tolerated in subjects with mild-to-moderate AD.
-
64/100
Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.
-
More open debates of practical experiences from different trial centres and sponsors are essential for optimizing trial designs and improving conditions for participants.
-
Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.
-
Alzheimer's disease (AD) is the most common cause of dementia among older people.
-
Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates.
-
Association of HT use and risk of AD may depend on timing of use.
-
β-Site amyloid precursor protein cleaving enzyme1 (BACE1) is one of the key enzymes involved in the processing of the amyloid precursor protein (APP) and formation of amyloid β peptide (Aβ) species.
-
No registered drug affects the deposition of Aβ in the brain of AD patients.
-
Main results Nine studies (from eight published reports) of 5149 individuals with mild cognitive impairment (however defined) were included in the review.
-
Neuropsychiatric symptoms such as agitation and delusions occur commonly in elderly patients with dementia and often cause significant distress.
-
70/100
Parkinson's disease dementia (PDD) is associated with cholinergic deficits.
-
In Alzheimer disease (AD), the perturbation of the endoplasmic reticulum (ER) calcium (Ca²⁺) homeostasis has been linked to presenilins, the catalytic core in γ-secretase complexes cleaving the amyloid precursor protein (APP), thereby generating amyloid-β (Aβ) peptides.
-
In the 3 studies combined, the data indicated that rofecoxib more than tripled the risk of confirmed CVT death (risk ratio = 3.57 [1.48-9.72], P = .004).
-
The cognitive functions of the patients in the CMG and WMG were improved after treatment.
-
Cognitive rehabilitation (CR) is a promising treatment approach for older adults with dementia because it aims at supporting the management of day-to-day problems.
-
Donepezil is safe and well tolerated.
-
Electroconvulsive therapy (ECT) is an effective strategy in some treatment-resistant patients with schizophrenia.
-
Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder QUESTION Question: Is atypical antipsychotic use associated with incident diabetes or hyperlipidaemia in older people without schizophrenia or bipolar disorder?
-
Twelve months' treatment with doxycycline or rifampin, alone or in combination, has no beneficial effects on cognition or function in AD.
-
Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo.
-
Two randomized controlled trials were included, one was scale A, and the other was scale B. The rates of abnormal liver function, withdrawal from treatment, and withdrawal due to adverse effects were higher in the treatment group (OR = 7.86, 95%CI: 2.50-24.69; OR = 4.70, 95%CI: 2.61-8.44; and OR = 5.47, 95%CI: 3.01-9.94; respectively) compared with the placebo group.
-
This study provides data on whether tailored nutritional care is beneficial to home-dwelling AD patients and their spouses.
-
A condensed protocol for communicating genetic risk for Alzheimer disease achieved similar educational results as an extended protocol in this study.
-
Studies have shown that donepezil could reduce the AD assessment scale-cognitive subscale (ADAS-Cog) score in MCI patients and improve the patient's attention and speed of response; however, it also has many side effects.
-
1680 participants were randomized over the recruitment period in MAPT study.
-
56/100
This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment.
From across this tag
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial
- Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
- Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
- The Lifestyle Intervention in memory clinics of General and academic Hospitals Trial (LIGHT): Rationale and study design of a randomized controlled trial to reduce modifiable dementia risk
- Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial
- Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?
- Home-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease: Feasibility Randomized Controlled Trial
- Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
- The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial